IRVINE, CA, AIVITA Biomedical has closed its Series B-2 financing round for up to $25 million.
AIVITA Biomedical, a private biotechnology company developing personalized vaccines for the treatment of cancer and prevention of COVID-19, has closed its Series B-2 financing round for up to $25 million. Financing was provided by several life sciences investment firms.
AIVITA Biomedical is engaged in the advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity differentiation to enable safe, efficient, and economical manufacturing systems that support its therapeutic pipeline and commercial line of skin care products.
(c) by Massinvestor, Inc. For contact info, please check out our about